clinical deal signal derived

{
  "input": {
    "type": "http",
    "method": "GET",
    "queryParams": {
      "lang": "en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)",
      "stage": "phase2 | phase3 | both (default: both)",
      "condition": "Disease area — e.g. \"Obesity\" | \"Cardiovascular\" | \"Oncology\" | \"Rare Neurological\" | \"Autoimmune\"",
      "deal_type": "acquisition | licensing | both (default: both)"
    }
  },
  "output": {
    "type": "json",
    "example": {
      "query_summary": {
        "as_of": "2026-06-07",
        "stage": "both",
        "condition": "Obesity",
        "deal_type": "both"
      },
      "market_context": {
        "approved_leaders": [
          "Semaglutide (Novo Nordisk — Wegovy)",
          "Tirzepatide (Lilly — Zepbound)"
        ],
        "big_pharma_strategic_need": "Roche, AstraZeneca, Pfizer, Amgen all need next-gen obesity assets. Roche acquired Carmot Therapeutics for $2.7B. AZ acquired Eccogene for obesity pipeline.",
        "total_addressable_market_usd_bn": 100
      },
      "recent_deal_comps": [
        {
          "deal": "Roche / Carmot Therapeutics",
          "year": 2023,
          "stage": "PHASE1/2",
          "mechanism": "GLP-1 peptide",
          "value_usd_bn": 2.7
        },
        {
          "deal": "AstraZeneca / Eccogene",
          "year": 2024,
          "stage": "PHASE2",
          "mechanism": "Small-molecule GLP-1",
          "value_usd_bn": 1.85
        },
        {
          "deal": "Amgen / ChemoCentryx",
          "year": 2022,
          "stage": "Approved",
          "mechanism": "C5aR1",
          "value_usd_bn": 3.7
        }
      ],
      "acquisition_targets": [
        {
          "asset": "Mazdutide (IBI362)",
          "risks": [
            "China geopolitical risk for IP transfer",
            "Phase 3 US/EU data needed before deal close"
          ],
          "stage": "PHASE3",
          "company": "Innovent Biologics (China)",
          "deal_comp": "Structure Day1 Biosciences (Pfizer) $1.25B + milestones — Phase 2 obesity asset. Mazdutide later-stage = premium.",
          "mechanism": "GLP-1/glucagon dual agonist",
          "probability": "High",
          "clinical_data": "Phase 3 China data strong — 14.5% body weight reduction at 52 weeks",
          "deal_rationale": "Ex-China rights available. Differentiated vs. semaglutide on muscle preservation. Lilly or Roche most likely acquirers.",
          "estimated_deal_value_usd_m": "800-2000"
        }
      ],
      "deal_timing_signals": "Obesity M&A is peak hot. Big pharma BD teams are actively searching — any Phase 2 readout with >10% weight loss and clean safety profile will attract inbound interest within 3-6 months of data release.",
      "licensing_opportunities": [
        {
          "asset": "CT-388 (dual GLP-1/GIP)",
          "notes": "Roche may sublicense ex-US rights to regional partners in Asia/LatAm",
          "company": "Carmot Therapeutics (acq. Roche)",
          "estimated_license_value_usd_m": "300-800"
        }
      ]
    }
  }
}